Information Provided By:
Fly News Breaks for February 22, 2016
TEVA, MYL, PRGO
Feb 22, 2016 | 05:43 EDT
Goldman Sachs analyst Jami Rubin downgraded Perrigo to Sell saying the stock, despite the recent selloff, "continues to trade at a premium that it does not deserve." Perrigo has morphed into a specialty pharmaceutical company as its consumer health business continues to struggle, Rubin tells investors in a research note. She prefers Mylan (MYL) and Teva (TEVA) in the generic space. The analyst cut her price target for Perrigo shares to $124 from $160. The stock closed Friday down 95c to $129.45.
News For PRGO;MYL;TEVA From the Last 2 Days
There are no results for your query PRGO;MYL;TEVA